Mobile website
Archive > Volume 29 Issue 11 > 2022,29(11):985-988. DOI:10.3872/j.issn.1007-385X.2022.11.004 Prev Next
Expert Forum
Interpretation of Chinese consensus on the construction of multidisciplinary team for management of immune checkpoint inhibitor-related toxicity
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Immunotherapy, based on immune checkpoint inhibitors (ICIs), has become the mainstay of treatment for solid tumors, with broad spectrum and definitive efficacy; however, the subsequent immune-related toxicity, namely immune-related adverse event (irAE), has increasingly become an obstacle to immunotherapy. At present, several guidelines or consensus have provided principled and specific guidance on the diagnosis, classification, treatment, and monitoring of irAE. Considering the management of irAE often involves multiple disciplines, the Chinese Society of Clinical Oncology (CSCO) immunotherapy committee, Antitumor Drug Safety Management Committee organized a panel of clinical experts and published“Chinese Consensus on the Construction of Multidisciplinary Team for Management of Immune Checkpoint Inhibitor-Related Toxicity”.As the author of the consensus, I hereby make a preliminary interpretation of the content of the consensus.
Keywords:
Project Supported:
Clc Number:
